Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Alecensa (alectinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

ALK inhibitor

Related drugs:

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK fusion	Lung Non-Squamous Non-Small Cell Cancer	ALK fusion	Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK positive	Neuroendocrine Tumor	ALK positive	Neuroendocrine Tumor	alectinib Sensitive: C1 - Off-label alectinib Sensitive : C1	alectinib Sensitive: C1 - Off-label alectinib Sensitive : C1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	atezolizumab + alectinib Sensitive: C2 – Inclusion Criteria atezolizumab + alectinib Sensitive : C2	atezolizumab + alectinib Sensitive: C2 – Inclusion Criteria atezolizumab + alectinib Sensitive : C2
ALK rearrangement	Solid Tumor	ALK rearrangement	Solid Tumor	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria bevacizumab + alectinib Sensitive : C2	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria bevacizumab + alectinib Sensitive : C2